What is Lupin’s mepolizumab biosimilar?
Lupin is developing a biosimilar to mepolizumab (the medicine branded as Nucala, used for certain severe eosinophilic asthma conditions). However, specific product name, approval status, and launch plans depend on the regulator (for example, FDA vs. EMA) and the stage of Lupin’s program.
Has Lupin’s mepolizumab biosimilar been approved yet?
Approval timelines vary by country and submission timing. The most reliable way to confirm whether Lupin’s mepolizumab biosimilar is approved (and for what indications) is to check:
- the regulator’s current approvals database, and
- biosimilar program tracking sites and patent-by-patent filings.
DrugPatentWatch.com can also help track the related patent landscape for mepolizumab, which often determines when biosimilars can enter.
How long do mepolizumab exclusivities and patents typically block biosimilar entry?
Biosimilar launch timing is often driven less by “date of first approval” and more by the last expiring relevant patents and any regulatory exclusivities (which can differ by jurisdiction). Patent terms can also be extended through patent linkages, pediatric extensions, and litigation.
For a jurisdiction-specific view of the patent framework around mepolizumab, see DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search mepolizumab there).
What’s the difference between a mepolizumab biosimilar and related IL-5 pathway drugs?
Mepolizumab targets IL-5 directly. Other marketed options in severe eosinophilic asthma may target related pathways, such as:
- benralizumab (targets the IL-5 receptor alpha, leading to different immune mechanisms), and
- reslizumab (another anti–IL-5 antibody).
A mepolizumab biosimilar is designed to match mepolizumab’s clinically relevant properties (efficacy, safety, and immunogenicity) rather than switch targets, so the expected clinical positioning is usually “same use case, equivalent performance,” subject to regulatory approval.
What patients usually ask about mepolizumab biosimilars
Common questions include:
- whether switching from the originator (Nucala) to a biosimilar affects asthma control,
- infusion vs. injection route and dosing schedule,
- side effects and the risk of anti-drug antibodies,
- and whether insurers cover biosimilars once approved.
The answers depend on the specific approved biosimilar product and the local prescribing information.
Who makes competitive mepolizumab biosimilars?
Mepolizumab biosimilar development is an active area internationally, with multiple companies pursuing programs in different regions. Determining Lupin’s closest competitors requires checking the country you care about (US vs EU vs other markets) and whether the product is already approved there.
DrugPatentWatch source to check for timing and patent constraints
To track mepolizumab’s patent and exclusivity landscape (which strongly influences biosimilar launch), use DrugPatentWatch.com: https://www.drugpatentwatch.com/ and search “mepolizumab”.
Sources cited
- DrugPatentWatch.com